Unicycive Therapeutics, Inc. cash flow to debt ratio of -15.74K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Unicycive Therapeutics, Inc.'s free cash flow has decreased 9.40% from $-28.65M last year to $-31.34M, signaling decreasing performance

Unicycive Therapeutics, Inc.'s debt to equity ratio is 0.03, which means that the company's assets are healthy financed, signaling financial stability.

Unicycive Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.10 last year to 0.03 today, signaling strengthened financials

Unicycive Therapeutics, Inc. has a net cash position, so leverage is healthy.

Unicycive Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Unicycive Therapeutics, Inc. has insufficient data to evaluate this check.

Unicycive Therapeutics, Inc.'s short-term assets of $48.96M exceed its short-term liabilities of $18.94M

Unicycive Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Unicycive Therapeutics, Inc.'s return on equity of -131.18%, is lower than 15.00%, indicating bad performance

Unicycive Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Unicycive Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Unicycive Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Unicycive Therapeutics, Inc. has negative free cash flow, indicating cash burn

Unicycive Therapeutics, Inc.'s yearly earnings has increased -27.70% since last year from $-36.73M to $-26.55M, signaling increasing performance

Unicycive Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -77.54% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Unicycive Therapeutics, Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

Unicycive Therapeutics, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Unicycive Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Unicycive Therapeutics, Inc. has insufficient data to evaluate this check.

Unicycive Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Unicycive Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Unicycive Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Unicycive Therapeutics, Inc. has insufficient data to evaluate this check.

Unicycive Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Unicycive Therapeutics, Inc. has a price-to-book ratio of 31.83x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Unicycive Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue